The new ACR guideline for the treatment of rheumatoid arthritis (RA) is technically solid, but the new recommendations miss some of the most topical issues in RA therapeutics. The fact that evidence from many high-quality clinical studies in RA was not deemed sufficient to support stronger recommendations is also worrying.
This is a preview of subscription content, log in via an institution to check access.
References
Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.39480 (2015).
Svensson, B. et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 52, 3360–3370 (2005).
Boers, M. et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309–318 (1997).
Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353, 1568–1573 (1999).
Verstappen, S. M. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66, 1443–1449 (2007).
Hetland, M. L. et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 54, 1401–1409 (2006).
Smolen, J. S. et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383, 321–332 (2014).
van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).
van Vollenhoven, R. F. et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205726 (2015).
Hambardzumyan, K. et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann. Rheum. Dis. 74, 1102–1109 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received support and grants for research from AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche and UCB, and has received consultancy honoraria from AbbVie, Biotest, Bristol-Myers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB and Vertex.
Supplementary information
Supplementary Box
Topics to include in future guidelines (PDF 104 kb)
Rights and permissions
About this article
Cite this article
van Vollenhoven, R. Missed opportunities in the 2015 ACR guideline for RA treatment. Nat Rev Rheumatol 12, 135–136 (2016). https://doi.org/10.1038/nrrheum.2015.181
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.181
- Springer Nature Limited